Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2026)

Black Diamond Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• Quarterly Research & Development fell 33.34% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 37.74% YoY) and the FY2025 annual result came in at $33.6 million, down 34.6% from the prior year.
• Research & Development was $7.0 million for Q1 2026 at Black Diamond Therapeutics, up from $6.3 million in the prior quarter.
• Across five years, Research & Development topped out at $17.8 million in Q1 2022 and bottomed at $6.3 million in Q4 2025.
• A 5-year average of $12.7 million and a median of $13.2 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development gained 4.65% — and 2025, when it plunged 48.8%.
• Black Diamond Therapeutics' Research & Development stood at $14.6 million in 2022, then climbed by 4.65% to $15.3 million in 2023, then dropped by 19.57% to $12.3 million in 2024, then plunged by 48.8% to $6.3 million in 2025, then grew by 11.23% to $7.0 million in 2026.
• Business Quant data shows BDTX's Research & Development at $7.0 million in Q1 2026, $6.3 million in Q4 2025, and $7.4 million in Q3 2025.